Micap Share Discussion Threads

[shirishg] 03/3/2005 14:04

Post removed by ADVFN

[raynern] 02/3/2005 16:57

well we can put 2 + 2 together and get out of the other end, Micap + Bioprogress + unnamed Pharma = Mega bucks for all concerned. I doubt you will see many sellers when that's announced :-)

[zinco] 02/3/2005 16:39

Not while the seller remains it wont....;-)))

[sharedoc] 02/3/2005 16:30

If and when the news does come, the share price will go whooooooosh

[pitwits] 02/3/2005 16:00

Just that. News imminent. In their whispers column, or whatever the equivalent is.

[pomp circumstance] 02/3/2005 13:16

what do they say?

[pitwits] 02/3/2005 13:13

LOL! no mention of the express rumour today that a deal is imminent?

[shirishg] 27/2/2005 22:28

Post removed by ADVFN

[sharedoc] 27/2/2005 22:10

I managed to speak to mike on Fri. He would'nt divulge any Info. about the smoking cessation products, In his own words he said what a pleasure it was to be involved with BPRG (this sounds very positive as it implies that their allaince is going well). He also mentioned the fact that SKP have untill the end of March to name any further drugs that they may use Micap's technology for, sounds like March could be a good month for further news updates. Just speculating on a full licensing deal with BPRG + as yet unknown US company for nicotine products to aid smoking cessation is very exciting, just imagine what it would do to the market cap. of Micap, could easily double or treble in no time at all.

[unionhall] 25/2/2005 17:06

Spoke to Ann(e) Picton, PA to Mike Brennand.

Mike is out of the country until Tuesday.

Anne does not think there is any announcement imminent.

Suggested I call back to Michael Norris on Monday.

Anybody got (reasonable) any questions if I do ?

[pomp circumstance] 25/2/2005 14:39

why dnt you do it?

[xxxyyy] 25/2/2005 14:22

can any micap holders contact micap to enquire when news of the stop smoking product evaluation with bioprogress will be revealed as the expiry date for the 6month evaluation was yesterday. Thanks

[pomp circumstance] 25/2/2005 11:41

what a stupid comment to make!!!

Regardless of what people paid, they have what they are today.

They have to wait exactly the same time as thosde who buy today, but dont have to pay CGT on the gain!!!!

:)

[shirishg] 25/2/2005 11:41

Post removed by ADVFN

[shirishg] 25/2/2005 11:40

Post removed by ADVFN

[tony5505] 25/2/2005 00:48

From this mornings IC :

Micap acquires Rendel & Scherer

 
Micap has unveiled plans to buy Germany-based Rendel & Scherer for up to E1m. Micap is focused on technology that uses yeast to help deliver active flavours and has been on the lookout for acquisitions that expand its skills set.

Rendel was set up in 2002 to focus on the food industry and it has expanded its activities into the nutriceutical and cosmeceutical markets. It is expected to make a profitable contribution in its first year. Broker Teather & Greenwood expects 2005 sales of £750,000 and losses of £1m.


To date sales at Micap have proved disappointing however the foray into Germany should bring new opportunities for cross selling.

[pomp circumstance] 23/2/2005 13:43

Shhhhh!!!!!

[rambutan2] 23/2/2005 12:54

has to be good news - i think?

[pomp circumstance] 23/2/2005 07:03

RNS Number:9141I
MICAP PLC
23 February 2005



For release

23 February 2005

Micap plc

("Micap" or "the Company")

Acquisition of Rendel & Scherer GbR ("R&S") for up to Euro1.0 million

Micap plc, the UK microencapsulation specialist, announces the acquisition of
Rendel & Scherer GbR, a company with a strong reputation as a provider of
innovative microencapsulation solutions, originally to the food industry, and
more recently, a growing expertise within the Nutriceutical and Cosmeceutical
markets. The acquisition is expected to make a positive contribution to Group
profitability in its first year.

Michael Brennand, CEO of Micap, commented: "This is a very exciting acquisition,
which will bring new skills and intellectual property into the Group across a
wide range of microencapsulation technologies, and will help in establishing
Micap as the clear industry leader for industrial companies facing
microencapsulation challenges. We shall look to both R&S and Applied Analysis to
assist in our drive to commercialisation in the natural healthcare market, where
the opportunities for new product developments utilising microencapsulation are
significant".

Based in Bremerhaven, Germany, and founded in 2002, R&S is currently working on
a number of revenue generating projects, including long term royalty and
contractual arrangements with, inter alia, a leading German flavour house and a
supplier of yeast/cultures to the bakery and wine industry. R&S has also
recently supplied essential oils encapsulated in a novel delivery system to a
cosmetics partner, for use in a newly launched product. In addition R&S is a
partner in a European Network project called Flow-cap, where it is part of a
consortium of organisations developing a system to protect live probiotic
bacteria during processing. This system has applications in both the cheese and
candy industries.

The acquisition by Micap of the entire issued and potentially issuable share
capital of R&S, is for an initial consideration of Euro 0.25 million, with a
further Euro 0.75 million of deferred consideration subject to performance (see
footnote). The consideration is payable in a mixture of cash and ordinary shares
in Micap plc. A new company, Micap GmbH, has been created to acquire the
business of R&S, which is an established partnership between Mr Jorg Rendel and
Mr Carlo Scherer, who will both remain as directors of Micap GmbH.

Jorg Rendel, Director of R&S added: "Carlo and I are delighted to be joining the
Micap group, and we look forward to the opportunity of utilising Micap's
exciting technologies and bringing our know-how, experience and skills in
microencapsulation solutions to a wide range of new challenges".


- Ends -

For further information:

Micap plc Tel: [phone]
Mike Brennand, Chief Executive [phone]

Michael Norris, Finance Director [phone]

Binns & Co Tel: [phone]
Chris Steele/Tarquin Edwards [phone] / [phone]




Footnote

The deferred consideration of up to Euro 750,000 is payable to the Vendors (Messrs.
Rendel and Scherer) subject to achievement of turnover targets as follows:

Calendar year Turnover target Consideration in cash Consideration in shares

2005 Euro 500,000 Euro 100,000 Euro 100,000
Euro 750,000 No further payment Further Euro 50,000
2006 Euro 1,300,000 Euro 150,000 Euro 150,000
Euro 2,000,000 No further payment Further Euro 150,000
2007 Euro 1,300,000 Euro 25,000 Euro 25,000

In assessing the number of shares in the Company to be issued to the Vendors
pursuant to the deferred consideration referred to above, the value attributed
to each share shall be the average of the middle market quotations of shares in
the Company as derived from the AIM market daily list for the thirty days prior
to the date on which the payments become due.

The company can, at its sole discretion, opt to pay the share element of the
deferred consideration in cash.

Notes to editors:

About Micap
Micap listed on AIM in August 2003 and is a UK technology licensing company
specialising in the microencapsulation of active ingredients within yeast
cells. For further details visit www.micap.co.uk Microencapsulation is a process
whereby tiny droplets of liquid or particles of solid material are coated with a
continuous film of polymeric material. Microcapsules have several benefits,
including conversion of liquids to solids; separating reactive compounds;
protecting substances against environmental factors; and improving the material
handling properties. Micap's unique proprietary technology involves using killed
yeast cells as natural capsules to protect the active ingredient. Yeast
encapsulation can protect active ingredients against high temperatures, the
effects of the sun, pressure and degradation through exposure to the air. The
natural affinity of yeast cells for mucous membranes can also be exploited for
targeted drug delivery.





This information is provided by RNS
The company news service from the London Stock Exchange

END
ACQTTMRTMMATBIA

[tony5505] 23/2/2005 00:25

A little snippet from the Daily Express 22/2/05
SHARE WHISPER "Yeast encapsulation group Micap which has been testing products against the hospital superbug MRSA, rebounded 1p to 28.5p. Shares have lost nearly two thirds of their value over the past year but sentiment could improve with updates on research projects"

[sharedoc] 21/2/2005 10:55

Its just started to wake up, bid up to 26p, it could be the start of something